KRAS G12S clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
Our lead scientists for KRAS G12S research studies include Zev Wainberg, MD.